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BACKGROUND
Evolocumab, a fully human monoclonal antibody directed against proprotein con-
vertase subtilisin–kexin type 9, is widely used in adult patients to lower low-density 
lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozy-
gous familial hypercholesterolemia are not known.
METHODS
We conducted a 24-week, randomized, double-blind, placebo-controlled trial to 
evaluate the efficacy and safety of evolocumab in pediatric patients with heterozy-
gous familial hypercholesterolemia. Patients 10 to 17 years of age who had received 
stable lipid-lowering treatment for at least 4 weeks before screening and who had an 
LDL cholesterol level of 130 mg per deciliter (3.4 mmol per liter) or more and a 
triglyceride level of 400 mg per deciliter (4.5 mmol per liter) or less were randomly 
assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab 
(420 mg) or placebo. The primary end point was the percent change in LDL cho-
lesterol level from baseline to week 24; key secondary end points were the mean 
percent change in LDL cholesterol level from baseline to weeks 22 and 24 and the 
absolute change in LDL cholesterol level from baseline to week 24.
RESULTS
A total of 157 patients underwent randomization and received evolocumab (104 pa-
tients) or placebo (53 patients). At week 24, the mean percent change from baseline 
in LDL cholesterol level was −44.5% in the evolocumab group and −6.2% in the 
placebo group, for a difference of −38.3 percentage points (P<0.001). The absolute 
change in the LDL cholesterol level was −77.5 mg per deciliter (−2.0 mmol per liter) 
in the evolocumab group and −9.0 mg per deciliter (−0.2 mmol per liter) in the pla-
cebo group, for a difference of −68.6 mg per deciliter (−1.8 mmol per liter) (P<0.001). 
Results for all secondary lipid variables were significantly better with evolocumab 
than with placebo. The incidence of adverse events that occurred during the treat-
ment period was similar in the evolocumab and placebo groups.
CONCLUSIONS
In this trial involving pediatric patients with familial hypercholesterolemia, evo-
locumab reduced the LDL cholesterol level and other lipid variables. (Funded by 
Amgen; HAUSER-RCT ClinicalTrials.gov number, NCT02392559.)
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Familial hypercholesterolemia is a genetic condition characterized by an ele-vated plasma concentration of low-density 
lipoprotein (LDL) cholesterol starting at birth and 
an increased risk of premature atherosclerotic 
cardiovascular disease.1 With an estimated prev-
alence of 1 in 250 in the general population, 
heterozygous familial hypercholesterolemia is the 
most frequent monogenic disorder and a major 
heritable cause of atherosclerotic cardiovascular 
disease worldwide.2
Familial hypercholesterolemia is caused by 
variants in genes encoding proteins involved in 
the clearance of LDL particles. More than 90% of 
the patients with genetically confirmed familial 
hypercholesterolemia have mutations in the gene 
encoding the LDL receptor (LDLR). Familial hyper-
cholesterolemia is also caused by mutations in 
genes encoding apolipoprotein B (APOB), propro-
tein convertase subtilisin–kexin type 9 (PCSK9), 
or LDL receptor adaptor protein 1 (LDLRAP1).1 
Naturally occurring loss-of-function PCSK9 vari-
ants are associated with low LDL cholesterol lev-
els starting at birth and a decreased incidence of 
atherosclerotic cardiovascular disease in adult-
hood.3 Growing evidence suggests that the patho-
physiological atherosclerotic changes begin early 
in life in patients with familial hypercholesterol-
emia and that reduction of LDL cholesterol levels 
in childhood may be important to prevent under-
lying atherosclerotic cardiovascular disease.4 
Statins are the standard preferred therapy for the 
pharmacologic treatment of familial hypercho-
lesterolemia in pediatric patients. Ezetimibe may 
be added, and current guidelines recommend 
treatment initiation at the age of 8 or 10 years 
in heterozygous familial hypercholesterolemia.4,5 
Despite appropriate treatment, guideline-recom-
mended LDL cholesterol levels are not achieved 
in some patients with familial hypercholesterol-
emia.5-7
Evolocumab is a fully human monoclonal an-
tibody directed against PCSK9. It prevents PCSK9 
from degrading LDL receptor, which increases 
the availability of LDL receptor and thus reduces 
LDL cholesterol levels up to 60% in adults.8 Evo-
locumab was initially approved in 2015 to reduce 
LDL cholesterol levels in adults with hyperlipid-
emia, including familial hypercholesterolemia, 
and in 2017 to reduce the risk of myocardial in-
farction, stroke, and revascularization in adults 
with atherosclerotic cardiovascular disease.9-12 
Here, we describe the results of HAUSER-RCT, a 
randomized, placebo-controlled, parallel-group, 
phase 3 trial of evolocumab. The trial was designed 
to assess the efficacy and safety of evolocumab as 
an add-on therapy to appropriate statin treatment, 
with or without ezetimibe, in pediatric patients 
with familial hypercholesterolemia in whom LDL 
cholesterol goals had not been achieved.
Me thods
Trial Design and Oversight
We conducted the trial from March 2016 through 
November 2019. The first patient was enrolled on 
March 24, 2016, and the last on May 30, 2019; the 
last visit with a trial patient was on November 25, 
2019. The date of the database lock was Febru-
ary 25, 2020. Patients underwent screening and 
randomization at 47 sites across 23 countries in 
North America, Latin America, Europe, and the 
Asia–Pacific region. The trial consisted of a 
screening period with a maximum duration of 
8 weeks followed by a 24-week double-blind treat-
ment phase. Diagnosis of heterozygous familial 
hypercholesterolemia was made by means of ge-
netic testing or according to applicable clinical 
diagnostic criteria for heterozygous familial hy-
percholesterolemia (criteria outlined by the Simon 
Broome Register Group, the Dutch Lipid Clinic 
Network, and the Make Early Diagnosis to Pre-
vent Early Deaths [MEDPED] program). Biomark-
er measurements and pharmacogenetic testing 
were performed after written informed consent to 
participate in the trial had been obtained (from 
the patient or a legal guardian) in accordance with 
local regulations. An open-label extension study 
(HAUSER-OLE) is currently ongoing and was of-
fered to patients who completed the present trial.
Amgen sponsored and designed the trial13; 
the protocol and statistical analysis plan are 
available with the full text of this article at 
NEJM.org. The trial protocol and informed-con-
sent form were reviewed and approved by inde-
pendent ethics committees or institutional review 
boards at each trial site. Trial activities and over-
sight were conducted in accordance with the 
principles of the Declaration of Helsinki, the 
Good Clinical Practice guidelines of the Interna-
tional Conference on Harmonisation, and rele-
vant regulatory requirements. An independent data 
monitoring committee and the independent bio-
statistical group oversaw efficacy and safety data 
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on a regular basis. The first draft of the manu-
script was written by an Amgen medical writer, in 
collaboration with and under the direction of the 
first, second, eighth, and last authors; all the co-
authors interpreted the results and contributed to 
the development of subsequent manuscript drafts 
and vouch for the completeness and accuracy of 
the data and for the fidelity of the trial to the pro-
tocol.
Patients and Randomization
Detailed information on patient eligibility criteria 
was reported previously13 (Table S1 in the Sup-
plementary Appendix, available at NEJM.org). 
Patients 10 to 17 years of age with heterozygous 
familial hypercholesterolemia who were follow-
ing a low-fat diet, who had received stable lipid-
lowering therapy for at least 4 weeks before 
screening, and who had an LDL cholesterol level 
of 130 mg per deciliter (3.4 mmol per liter) or more 
and a triglyceride level of 400 mg per deciliter 
(4.5 mmol per liter) or less were screened. Pa-
tients were randomly assigned in a 2:1 ratio to 
receive monthly subcutaneous injections of either 
evolocumab (420 mg) or placebo for 24 weeks. 
Randomization was stratified according to the 
LDL cholesterol level at the time of screening 
(<160 vs. ≥160 mg per deciliter [4.1 mmol per 
liter]) and the age at baseline (<14 vs. ≥14 years).
End Points
The primary efficacy end point was the percent 
change in LDL cholesterol level from baseline to 
week 24. Secondary end points included the mean 
percent change in LDL cholesterol level from 
baseline to weeks 22 and 24, the absolute change 
in LDL cholesterol level from baseline to week 24, 
and the percent changes in non–high-density lipo-
protein (HDL) cholesterol level, apolipoprotein B 
level, the ratio of total cholesterol to HDL choles-
terol, and the ratio of apolipoprotein B to apoli-
poprotein A1 from baseline to week 24. Details 
regarding other tertiary and exploratory end points 
are provided in the Supplementary Appendix.
Safety
Safety analyses included the incidence of adverse 
events that occurred during the treatment period. 
Laboratory assessments included levels of hor-
mones and vitamins A, D, E, and K and the devel-
opment of anti-evolocumab antibodies. Specific 
safety tests were conducted at baseline and week 
24 to assess cognitive function (Cogstate battery 
of cognitive tests), pubertal growth and develop-
ment (Tanner staging), carotid intima–media 
thickness for atherosclerosis progression,13 and 
changes on electrocardiography (ECG).
Statistical Analysis
A sample of 150 patients who were randomly 
assigned in a 2:1 ratio to receive evolocumab or 
placebo was calculated to be sufficient to gener-
ate 99% power to test the superiority of evolocu-
mab (420 mg) over placebo for the primary end 
point. The sample size was calculated with the use 
of a two-sided t-test with a type I error rate of 0.05 
and the following assumptions: a 40% lower level 
of LDL cholesterol with evolocumab than with 
placebo, a common standard deviation of 20%, 
and 20% of patients discontinuing the assigned 
regimen before trial completion (Fig. S1). Efficacy 
and safety analyses included all randomly as-
signed patients who received at least one dose of 
evolocumab or placebo. Additional information 
is provided in the Supplementary Appendix.
R esult s
Patients
From March 2016 through May 2019, a total of 
158 patients underwent randomization, of whom 
157 (99%) received either evolocumab (104 pa-
tients) or placebo (53 patients) (Fig. S2). The 
demographic and clinical characteristics of the 
patients at baseline were generally balanced be-
tween the two groups (Table 1). The mean (±SD) 
age of the patients was 13.7±2.4 years, 88 pa-
tients (56%) were female, and 133 (85%) were 
White. A total of 18 patients (11%) had two or 
more risk factors for atherosclerotic cardiovas-
cular disease; 52 (33%) had a first-degree family 
history of premature atherosclerotic cardiovas-
cular disease. All the patients received a diagno-
sis of heterozygous familial hypercholesterol-
emia at screening. A total of 104 patients (66%) 
received a molecular diagnosis of familial hyper-
cholesterolemia; of these, 100 patients (96%) had a 
mutation in LDLR, 3 (3%) had a mutation in APOB, 
and 1 (1%) had a mutation in PCSK9. At baseline, 
124 patients (79%) were using high-intensity or 
moderate-intensity statins, and 21 (13%) were 
also taking ezetimibe. No changes in background 
lipid-lowering therapy were reported at any time 
during the trial.
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Mean — yr 13.7±2.3 13.7±2.5
Distribution — no. (%)
<14 yr 48 (46) 25 (47)
≥14 yr 56 (54) 28 (53)
Female sex — no. (%) 61 (59) 27 (51)
White race — no. (%)† 89 (86) 44 (83)
Weight — kg
Median (IQR) 55.3 (48.0–68.8) 53.3 (42.4–61.0)
10th percentile 35.7 35.8
90th percentile 79.0 80.6
Height — cm
Median (IQR) 161.5 (152.0–168.0) 158.5 (148.0–165.5)
10th percentile 143.8 143.0
90th percentile 173.0 175.2
BMI-for-age category — no. (%)‡
Underweight 2 (2) 2 (4)
Normal 62 (60) 36 (68)
Overweight 21 (20) 8 (15)
Obese 19 (18) 7 (13)
Geographic region — no. (%)
North America 12 (12) 10 (19)
Europe 68 (65) 35 (66)
Latin America 18 (17) 8 (15)
Asia–Pacific 6 (6) 0
Cardiovascular risk factors — no. (%)§
Hypertension 2 (2) 3 (6)
Type 2 diabetes mellitus 1 (1) 0
Family history of premature CHD 31 (30) 21 (40)
Low HDL cholesterol 40 (38) 18 (34)
Diagnosis of heterozygous FH — no. (%) 104 (100) 53 (100)
Genetic
LDLR mutation 70 (67) 30 (57)
APOB mutation 2 (2) 1 (2)
PCSK9 gain-of-function mutation 0 1 (2)
Clinical
Simon Broome Register Group criteria 9 (9) 7 (13)
Dutch Lipid Clinic Network criteria 22 (21) 10 (19)
MEDPED program criteria 1 (1) 4 (8)
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Efficacy
The mean (±SD) level of LDL cholesterol at base-
line was 184.3±45.6 mg per deciliter (4.8±1.2 
mmol per liter). Results for the primary and sec-
ondary efficacy end points were significantly bet-
ter with evolocumab than with placebo (P<0.001 
for all comparisons, with adjustment for multiple 
comparisons). At week 24, the mean percent 
change in LDL cholesterol level was −44.5% in 
the evolocumab group and −6.2% in the placebo 
group, for a difference of −38.3 percentage points 
(95% confidence interval [CI], −45.5 to −31.1). 
The mean absolute change in LDL cholesterol 
level from baseline to week 24 was −77.5 mg per 
deciliter (−2.0 mmol per liter) in the evolocumab 
group and −9.0 mg per deciliter (−0.2 mmol per 
liter) in the placebo group, for a difference of 
−68.6 mg per deciliter (95% CI, −83.1 to −54.0) 
(−1.8 mmol per liter [95% CI, −2.1 to −1.4]) 
(Table 2).
The efficacy of evolocumab for LDL choles-
terol reduction was maintained throughout the 
trial (Fig. 1). At weeks 22 and 24, the mean percent 
change from baseline in LDL cholesterol level was 
−48.0% in the evolocumab group and −5.9% in 
the placebo group, for a difference of −42.1 per-
centage points (Table 2). An LDL cholesterol re-
duction of more than 50% at week 22 was achieved 
in 60 of 97 patients (62%) in the evolocumab 
group and 0 of 49 patients in the placebo group. 
Similarly, at week 24, a total of 43 of 96 patients 






Statin use — no. (%) 104 (100) 52 (98)
High intensity 19 (18) 7 (13)
Moderate intensity 63 (61) 35 (66)
Low intensity or unknown intensity 22 (21) 10 (19)
Ezetimibe — no. (%) 13 (12) 8 (15)
Lipid variables¶
LDL cholesterol — mg/dl 185.0±45.0 183.0±47.2
Non-HDL cholesterol — mg/dl 203.8±47.3 200.2±48.2
Total cholesterol — mg/dl 250.7±47.0 247.3±49.5
HDL cholesterol — mg/dl 46.8±12.0 47.2±11.9
Median triglycerides (IQR) — mg/dl 86.8 (63.8–117.0) 78.0 (62.5–101.0)
Median lipoprotein(a) (IQR) — nmol/liter 50.5 (18.0–126.5) 34.0 (21.0–147.0)
PCSK9 — ng/ml 277.2±92.1 294.2±101.3
*  Plus–minus values are means ±SD. Patients were randomly assigned in a 2:1 ratio to receive monthly subcutaneous 
injections of either evolocumab (420 mg) or placebo for 24 weeks. Data from all 157 patients were used for analysis. To 
convert the values for LDL cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides 
to millimoles per liter, multiply by 0.01129. Percentages may not total 100 because of rounding. CHD denotes coronary 
heart disease, FH familial hypercholesterolemia, HDL high-density lipoprotein, IQR interquartile range, LDL low-density 
lipoprotein, and MEDPED Make Early Diagnosis to Prevent Early Deaths.
†  Race was reported by the patient.
‡  The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. BMI-for-age cat-
egories are based on expert committee recommendations14-16 (underweight, <5th percentile; normal, ≥5th percentile to 
<85th percentile; overweight, ≥85th percentile to <95th percentile; and obese, ≥95th percentile).
§  Shown are hypertension and diabetes diagnoses as provided by the investigators and entered in the trial clinical re-
search form; no definition of hypertension was specifically used in the trial. A low HDL cholesterol level was defined as 
less than 40 mg per deciliter (1.0 mmol per liter) in patients 10 years of age to younger than 16 years of age, less than 
40 mg per deciliter in male patients 16 years of age or older, and less than 50 mg per deciliter (1.3 mmol per liter) in 
female patients 16 years of age or older.
¶  For lipoprotein(a), 2 patients in the placebo group had missing values; for proprotein convertase subtilisin–kexin type 9 
(PCSK9), 7 patients in the evolocumab group and 1 patient in the placebo group had missing values.
Table 1. (Continued.)
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tients (2%) in the placebo group had an LDL 
cholesterol reduction of more than 50% (Table 
S2). An LDL cholesterol level of less than 130 mg 
per deciliter at week 22 was achieved in 77 of 
97 patients (79%) in the evolocumab group and 
7 of 49 patients (14%) in the placebo group 
(Table S2). At week 24, an LDL cholesterol level 
of less than 130 mg per deciliter was achieved in 
71 of 96 patients (74%) in the evolocumab group 
and 10 of 44 patients (23%) in the placebo group 
(Table S2).
Evolocumab showed a benefit with respect to 
other secondary lipid-related end points, includ-
ing non-HDL cholesterol and apolipoprotein B 
(Table 2). Results of sensitivity analyses of the 
primary and secondary end points, including an 
analysis in which assessments were made out-
side the prespecified time window of week 24 
(Table S3), were consistent with the results of the 
primary analysis (Table S3). The primary end-
point analysis at the patient level showed a con-
sistently greater reduction in LDL cholesterol lev-
els with evolocumab than with placebo (Fig. S3).
Evolocumab showed a benefit with respect to 
the primary and secondary efficacy end points in 
additional subgroup analyses (Fig. 2). The effect 
of evolocumab on LDL cholesterol lowering was 
similar in patients younger than 14 years of age 
and those 14 years of age or older (Fig. 2). Fur-
thermore, the mean percent decrease in the 
lipoprotein(a) level at week 24 and at weeks 22 
and 24 was numerically greater with evolocumab 
than with placebo (Table 2). Evolocumab treat-
ment resulted in a reduction in the serum levels 
of circulating unbound PCSK9, with maximal 
suppression of PCSK9 and LDL cholesterol at 
week 22 correlating with a peak concentration of 
evolocumab (Fig. S4).
Safety
The incidence of adverse events that occurred 
during the treatment period was similar in the 
evolocumab group and the placebo group. A total 
of 64 patients (62%) in the evolocumab group and 
34 (64%) in the placebo group reported at least 
one adverse event (Table 3). One patient (1%) in 
the evolocumab group reported a serious adverse 
event of cholelithiasis that was not considered by 










Percent change in LDL cholesterol from baseline to 
wk 24 (95% CI)
−44.5 (−48.8 to −40.3) −6.2 (−12.3 to −0.2) −38.3 (−45.5 to −31.1) <0.001
Percent change in LDL cholesterol from baseline to 
wk 22 and 24 (95% CI)
−48.0 (−51.7 to −44.2) −5.9 (−11.1 to −0.6) −42.1 (−48.3 to −35.8) <0.001
Absolute change in LDL cholesterol from baseline to 
wk 24 (95% CI) — mg/dl
−77.5 (−86.1 to −68.9) −9.0 (−21.1 to 3.2) −68.6 (−83.1 to −54.0) <0.001
Percent change in non-HDL cholesterol from base-
line to wk 24 (95% CI)
−41.2 (−45.2 to −37.2) −6.1 (−11.8 to −0.5) −35.0 (−41.8 to −28.3) <0.001
Percent change in apolipoprotein B from baseline to 
wk 24 (95% CI)
−34.9 (−38.6 to −31.1) −2.4 (−7.7 to 3.0) −32.5 (−38.8 to −26.1) <0.001
Percent change in ratio of total cholesterol to HDL 
cholesterol from baseline to wk 24 (95% CI)
−35.0 (−38.6 to −31.4) −4.7 (−9.8 to 0.5) −30.3 (−36.4 to −24.2) <0.001
Percent change in ratio of apolipoprotein B to apoli-
poprotein A1 from baseline to wk 24 (95% CI)
−37.0 (−40.9 to −33.2) −0.6 (−6.2 to 4.9) −36.4 (−43.0 to −29.8)
Percent change in lipoprotein(a) from baseline to wk 
24 (95% CI)‡
−7.4 (−20.1 to 5.3) 1.7 (−17.0 to 20.5)
Percent change in lipoprotein(a) from baseline to wk 
22 and 24 (95% CI)‡
−10.3 (−18.7 to −1.9) 1.6 (−10.4 to 13.7)
*  Shown are least-squares means from the repeated-measures model, which includes trial group, stratification factor of age at baseline and 
LDL cholesterol level at the time of screening (from the interactive voice-response system), scheduled visit, and the interaction of treatment 
with scheduled visit as covariates.
†  The difference is the value in the evolocumab group minus the value in the placebo group. Differences are expressed as percentage points, 
except for the absolute change in LDL cholesterol level (expressed as milligrams per deciliter).
‡  Lipoprotein(a) was a tertiary end point.
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the investigators and data monitoring committee 
to be related to the drug; another patient in the 
evolocumab group had a nonserious treatment-
related adverse event of arthropathy that led to 
discontinuation of the drug (Table 3). The most 
common adverse events (>2% of the patients in 
either group) with a higher incidence (by >1 per-
centage point) in the evolocumab group than in 
the placebo group were headache, oropharyngeal 
pain, influenza, influenza-type illness, upper re-
spiratory tract infection, and constipation. In the 
evolocumab group, an injection-site reaction oc-
curred in 1 patient (1%), as compared with no 
patients in the placebo group (Table 3). Four 
patients in the evolocumab group (4%) discon-
tinued treatment with the drug: 1 had a nonseri-
ous treatment-related adverse event of arthropathy 
(mentioned above), 2 requested discontinuation, 
and 1 missed a scheduled visit at which the final 
dose would have been administered.
Additional Efficacy and Safety Assessments
At week 24, mean changes from baseline in pu-
bertal development (Tanner stage for male pa-
tients and female patients [Table S4]) and growth 
variables (height, weight, and body-mass index 
[Table S9]) were similar in the evolocumab and 
placebo groups. Results for laboratory variables 
(including levels of steroid hormones, fat-soluble 
vitamins [vitamins A, D, E, and K], glucose, and 
glycated hemoglobin) were similar in the two 
groups at week 24 (Table S5). Changes from base-
line in carotid intima–media thickness (Table S6), 
neurologic assessment with the Cogstate battery 
of cognitive tests (Table S7), and ECG measures 
(Table S8) at week 24 were similar in the evo-
locumab and placebo groups. Anti-evolocumab 
antibodies developed in no patients during the 
trial, and no onset of diabetes was observed 
(Table 3).
Discussion
In this multicenter, randomized, controlled trial 
involving pediatric patients with heterozygous 
familial hypercholesterolemia, the PCSK9 inhibi-
tor evolocumab, when added to statin therapy 
with or without ezetimibe, was associated with a 
Figure 1. Mean Percent Change in Low-Density Lipoprotein (LDL) Cholesterol Level.
Shown are the unadjusted means and 95% confidence intervals for the percent change in LDL cholesterol level from baseline through 
the end of the trial at each scheduled visit. No imputation was used for missing values. Arrows indicate the subcutaneous administra-
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significantly greater reduction in the LDL cho-
lesterol level from baseline to week 24 than 
placebo (difference, −38.3 percentage points or 
−68.6 mg per deciliter). At weeks 22 and 24, the 
between-group difference in the mean percent 
change from baseline in LDL cholesterol level was 
−42.1 percentage points. Significant benefits 
with respect to other lipid variables in this pedi-
atric population were also observed. No safety 
concerns emerged from the analyses of the 
safety data.
Statins, ezetimibe, and bile acid–binding res-
ins are currently approved therapies to lower 
LDL cholesterol levels in pediatric patients with 
heterozygous familial hypercholesterolemia. De-
spite these medications, a recent European study 
showed that guideline-recommended LDL cho-
lesterol goals of less than 130 mg per deciliter, 
more modest than those for adults,1 were not 
achieved in 41 to 56% of these pediatric patients 
in most countries, although treatment may not 
have been appropriate in all the patients studied.7 
In the present trial, 124 patients (79%) were re-
ceiving high-intensity or moderate-intensity statins, 
and only a minority (21 patients [13%]) were 
receiving ezetimibe. Background lipid-lowering 
treatment reflected the diversity of the real-life 
management of pediatric familial hypercholes-
terolemia in the 23 countries from which the 
participants originated.
Figure 2. Subgroup Analysis of Efficacy End Points.
Shown are forest plots of the between-group difference (evolocumab minus placebo) in the percent change in LDL cholesterol level 
from baseline to the mean of weeks 22 and 24 and to week 24 according to subgroup. A repeated-measures model was used for the 
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Statins are currently the first-line treatment 
for pediatric patients who may need pharmaco-
logic therapy. Results of a recent study suggest 
that early initiation of statin treatment reduces 
subclinical atherosclerosis progression (as mea-
sured by carotid intima–media thickness), which 
is likely to result in a decrease in clinical athero-
sclerotic cardiovascular disease events at later 
stages of life.17 Despite the fact that the recom-
mended statin dose in the pediatric population 
is lower than in adults, the care of the majority 
of pediatric patients with familial hypercholes-
terolemia will be adequately managed with 
statins with or without ezetimibe and will not 
involve additional treatment. However, LDL cho-
lesterol goals are not attained in some patients 
owing to limited drug response, side effects, or 
poor treatment adherence. The results of the 
present trial suggest that if an additional therapy 
is indicated, evolocumab might be considered. 
Newer potential treatments such as bempedoic 
acid,18 gemcabene,19 small interfering RNA against 
PCSK9 (inclisiran),20 and the monoclonal antibody 
against angiopoietin-like 3 inhibitor (evinacu-
mab)21 have not yet been evaluated in pediatric 
patients with heterozygous familial hypercholes-
terolemia.
A few studies have examined the efficacy and 
safety of PCSK9 inhibitors in a limited number 
of pediatric patients with heterozygous familial 
hypercholesterolemia. The Trial Evaluating PCSK9 
Antibody in Subjects with LDL Receptor Abnor-
malities (TESLA)22 and the Trial Assessing Long 
Term Use of PCSK9 Inhibition in Subjects with 
Genetic LDL Disorders (TAUSSIG)10 included a 
total of 15 pediatric patients, all of whom had 
homozygous familial hypercholesterolemia. In this 
small group of patients, the safety profile of evo-
locumab was similar to that of placebo, and results 
for LDL cholesterol levels and other lipid variables 
were better with evolocumab. The ODYSSEY KIDS 
study, a phase 2, open-label, dose-finding study 
involving 42 pediatric patients with heterozygous 
familial hypercholesterolemia, showed a significant 
reduction in LDL cholesterol levels from baseline 
to week 8 with alirocumab.23
Throughout the present 6-month trial, 153 of 
157 patients (97%) received all planned doses of 
evolocumab or placebo, and among the 104 who 
received evolocumab, binding or neutralizing 
antibodies developed in no patients. No trends 
indicative of clinically important treatment-re-
lated laboratory or vital-sign abnormalities, ab-
normal physical examination findings (including 
findings on growth and pubertal development), 
or cognitive changes were observed. Moreover, 
there was no evidence of clinically relevant ef-
fects of evolocumab on steroid hormone biosyn-
thesis or on levels of vitamins (A, D, E, and K). 
Both the evolocumab and placebo groups received 
subcutaneous injections every 4 weeks. No patient 
dropped out owing to adverse events related to 
injection.
Our results include safety and efficacy data 
from this randomized, placebo-controlled trial 
of a PCSK9 inhibitor in pediatric patients with 
heterozygous familial hypercholesterolemia. The 
response to and safety of evolocumab at 24 weeks 
were consistent in all prespecified subgroups. 






no. of patients (%)
Any adverse event 64 (62) 34 (64)
Serious adverse event 1 (1) 0




Nonserious 1 (1) 0
Most common adverse events
Nasopharyngitis 12 (12) 6 (11)
Headache 11 (11) 1 (2)
Oropharyngeal pain 7 (7) 0
Influenza 6 (6) 2 (4)
Upper respiratory tract infection 6 (6) 1 (2)
Gastroenteritis 5 (5) 4 (8)
Pyrexia 3 (3) 3 (6)
Constipation 3 (3) 0
Influenza-like illness 3 (3) 0
Injection-site reaction 1 (1) 0
Laboratory results at wk 24
Aminotransferase level >3× ULN 0 0
Creatine kinase level >5× ULN 0 0
Development of anti-evolocumab antibodies† 0 —
*  ULN denotes the upper limit of the normal range.
†  Anti-evolocumab antibody assessment by means of an electrochemilumines-
cence-based immunoassay was performed at day 1 (randomization), week 
12, and week 24 (end of the trial). None of the patients tested positive at any 
time point.
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However, the present trial has certain limitations. 
Despite the fact that it was conducted in 23 coun-
tries and five continents, there was a preponder-
ance of White patients. The relatively short dura-
tion of the trial precluded the assessment of the 
effects of evolocumab on carotid intima–media 
thickness, neurocognition, and growth and de-
velopment. The long-term safety and efficacy of 
evolocumab in the management of familial hy-
percholesterolemia in pediatric patients will re-
quire further study.
We found that monthly evolocumab provided 
substantial LDL cholesterol lowering at 24 weeks 
when added to background lipid-lowering thera-
py in pediatric patients with heterozygous famil-
ial hypercholesterolemia.
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